Ground zero: first humans receive experimental COVID-19 drug
NCT ID NCT06965751
Summary
This is the first human study of a new drug called PDI204, which is being developed to treat or prevent COVID-19. Researchers are testing whether the drug is safe and how the body processes it in 32 healthy volunteers. Participants receive either the drug or a placebo as a single injection or infusion, then are monitored for side effects over three months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.